Drugs / Qsymia
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | QSYMIA | — | 2012-07-17 | fda.gov ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06905626 | Nov 2026 → Oct 2030 expected | — | University of Minnesota | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05378503 | Sep 2021 → Oct 2023 | obesity disorder | Alvogen Korea | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-08-21 | Alvogen Korea | Alvogen receives approval of Qsymia® in the Republic of Korea alvogen.com ↗ |
| 2017-09-06 | Alvogen Korea | Alvogen adds Qsymia to its anti-obesity portfolio in Korea alvogen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Qsymia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06905626 ↗ |
| Route | Oral | “It is also attractive in the context of prevention owing to its oral route of administration” NCT06905626 ↗ |